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Abstract
Background: Plasmodium falciparum (P. falciparum) malaria remains a significant
cause of mortality and morbidity throughout the world. Development of an effective
vaccine would be a key intervention to reduce the considerable social and
economic impact of malaria.
Methodology: We conducted a Phase Ia, non-randomized, clinical trial in 24
healthy, malaria-naı¨ve adults of the chimpanzee adenovirus 63 (ChAd63) and
modified vaccinia virus Ankara (MVA) replication-deficient viral vectored vaccines
encoding the circumsporozoite protein (CS) of P. falciparum.
Results: ChAd63-MVA CS administered in a heterologous prime-boost regime was
shown to be safe and immunogenic, inducing high-level T cell responses to CS.
With a priming ChAd63 CS dose of 56109 vp responses peaked at a mean of 1947
SFC/million PBMC (median 1524) measured by ELIspot 7 days after the MVA boost
and showed a mixed CD4+/CD8+ phenotype. With a higher priming dose of
ChAd63 CS dose 561010 vp T cell responses did not increase (mean 1659 SFC/
million PBMC, median 1049). Serum IgG responses to CS were modest and
peaked at day 14 post ChAd63 CS (median antibody concentration for all groups at
day 14 of 1.3 mg/ml (range 0–11.9), but persisted throughout late follow-up (day 140
median antibody concentration groups 1B & 2B 0.9 mg/ml (range 0–4.7).
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Conclusions: ChAd63-MVA is a safe and highly immunogenic delivery platform for
the CS antigen in humans which warrants efficacy testing.
Trial Registration: ClinicalTrials.gov NCT01450280
Introduction
Plasmodium falciparum (P. falciparum) malaria remains a cause of significant
mortality and morbidity throughout the world [1]. Though one vaccine, RTS,S,
has demonstrated promising results in Phase III trials, there remains a need to
develop an alternative, more effective vaccine. For more than 40 years it has been
known that it is possible to achieve high-level, sustained, protective immunity
against the pre-erythrocytic stages of P. falciparum infection through immuniza-
tion with the bites of .1000 infected, irradiated mosquitoes [2–5].
For many years the evidence suggested that antibodies against the major
sporozoite surface antigen, the circumsporozoite protein (CS), were responsible
for protection and this formed the basis of the design of the RTS,S vaccine [6].
However, based on data from murine adoptive transfer experiments and human
trials it now seems that CD8+ T cells specific for parasite-derived peptide/class I
MHC molecule complexes on the surface of infected hepatocytes are the primary
immune effectors [7–14]. Thus the goal in malaria vaccine development is a
vaccine that induces both humoral and cell-mediated immune responses resulting
in memory T and B cells that are specific for epitopes derived from parasite
proteins. Initially, it was thought that cytolysis of the infected hepatocyte by
parasite-specific CD8+ T cells was the primary effector mechanism, but recent data
suggest that the elimination of the infected hepatocytes is mediated by interferon-
gamma (IFN-c) released by CD8+ T cells [15]. Researchers at the University of
Oxford have been working for over 10 years to develop a pre-erythrocytic P.
falciparum malaria vaccine using the sporozoite and liver stage antigen ME-TRAP.
This antigen contains a fusion protein of multiple epitopes (ME: a string of 20
epitopes, mainly CD8+ T cell epitopes from pre-erythrocytic antigens) and the P.
falciparum pre-erythrocytic antigen thrombospondin-related adhesion protein
(TRAP) [16]. Multiple vectors for this antigen have been clinically tested
including DNA, fowl pox (FP) and modified vaccinia virus Ankara (MVA),
however T cell immunogenicity and clinical efficacy has been limited [17–19].
More recently, heterologous prime boost with Chimpanzee adenovirus 63
(ChAd63) and MVA, both expressing ME-TRAP, has been shown to be the most
immunogenic regimen to date, inducing more than 2400 IFNc producing T cells
post boost [20–22]. This heterologous prime-boost regime with the viral vectors
ChAd63 and MVA has been shown to induce the highest T cell responses in
humans of any vaccine platform, as well as strong antibody responses [23–25].
Simian adenoviruses are not known to cause pathology or illness in humans and
the prevalence of antibodies to chimpanzee origin adenoviruses is less than 5% in
Safety and Immunogenicity of ChAd63 and MVA CS
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humans residing in the USA [26]. In Equatorial Africa prevalence is higher. A
recent study in Kenya showed 4% of children to have high neutralising antibodies
to ChAd63 [27]. The presence of pre-existing antibodies to adenoviral vectors has
been an issue with human adenoviral vectors. However, data from the Phase IIb
efficacy study of ChAd63-MVA ME-TRAP showed no correlation between
neutralising antibodies to ChAd63 in volunteers prior to vaccination with their
subsequent T cell count post MVA boost, suggesting that even if neutralising
antibodies exist they may not limit immunogenicity [28]. The ChAd63 vector is
replication deficient as the essential E1 gene region has been deleted and the virus
only propagates in cells expressing E1 functions. This means the virus will not
replicate in human cells within the body. Pre-clinical bioavailability studies have
demonstrated no persistence of the ChAd63 vector 24 hours post intramuscular
administration. ChAd63 expressing various antigens has been administered to
over 400 individuals including children and has demonstrated an excellent safety
profile. Multiple studies have shown 561010 vp ChAd63 to be the optimal dose
[20, 21, 23, 28, 29].
With this platform the immune system is primed with a simian adenovirus
expressing an antigen and then boosted 8 weeks later with Modified Vaccinia
Ankara (MVA) expressing the same antigen. Several antigens have been trialled
using this platform [20, 22, 29] including ME-TRAP, which has shown sterile
protection in 21% of malaria-nai¨ve volunteers in controlled human malaria
infection (CHMI) [28]. In this study we combined this platform with the
circumsporozoite protein (CSP).
Methods
Objective
The objective of the study was to assess the reactogenicity and immunogenicity of
ChAd63 CS at two doses, 56109 virus particles (vp) and 561010 vp, administered
alone and in heterologous prime boost with MVA CS 26108 plaque forming
units (pfu) in healthy malaria-nai¨ve adults (Fig. 1).
ChAd63 CS and MVA CS Vaccines
Generation of the recombinant vectors has been previously described [21]. They
were manufactured under Good Manufacturing Practice conditions by the
Clinical Biomanufacturing Facility, University of Oxford (ChAd63 CS) and IDT
Biologika, Rosslau, Germany (MVA CS). Previous vectored vaccines expressing
the entire CS construct (CS) have been evaluated in Oxford, demonstrating only
modest T cell immunogenicity and efficacy on sporozoite challenge [30, 31]. The
poor immunogenicity of the standard full length CSP insert used in previous
vectors in clinical trials (CSO) [18, 31, 32], suggest that there may be an important
difference in the intrinsic immunogenicity of the previously tested CSO insert
compared to the ME-TRAP insert. Using information from multiple sources
Safety and Immunogenicity of ChAd63 and MVA CS
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[33–35], we have designed a novel CS antigen, to be used in this study, which
omits the extreme C-terminus of the protein that encodes the GPI-anchor
sequence. The CS insert is a codon-optimised cDNA encoding a C-terminally
truncated Plasmodium falciparum CS protein. Compared to wild-type, the
expressed protein lacks the C-terminal 14 amino acids, in order to inactivate the
GPI-anchor signal sequence. It also has a reduced number of NANP repeats. The
expression of CS is controlled by a CMV promoter and BGH polyA signal.
Briefly, ChAd63 CS was generated in suspension PC92-GMP cells and purified
by caesium chloride density-gradient centrifugation. MVA CS was generated in
chicken embryo fibroblasts (CEFs) and purified by sucrose density-gradient
centrifugation. Each vaccine lot underwent comprehensive quality control analysis
Fig. 1. CONSORT diagram of study progress. 39 volunteers were screened. Reasons for not meeting the inclusion criteria in 7 excluded volunteers were:
psychiatric morbidity (2), history of malignancy (2), one each of: history of headaches, Carbohydrate Deficient Transferrin (CDT) .3% and neutropenia.
doi:10.1371/journal.pone.0115161.g001
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to ensure that the purity, identity and integrity of the virus met pre-defined
specifications. Vaccine lots were stored at the clinical site in a temperature-
monitored freezer. The immuno-potency of the ChAd CS and MVA CS vaccines
was confirmed by immunogenicity evaluation in mice. To ensure on-going
stability for both vaccines, MVA CS was tested regularly by titration on CEFs in
addition to mouse potency testing and ChAd63 CS was tested by hexon
immunostaining for infectious units.
Participants
The study was conducted at the Clinical Research Centre, Royal College of
Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. Healthy, malaria-nai¨ve
males and non-pregnant females aged 18–50 were invited to participate in the
study. There was no selection of volunteers on the basis of pre-existing
neutralizing antibodies (NAb) to the ChAd63 vector prior to enrolment, (see
supporting information for the full list of inclusion and exclusion criteria).
Study Design
This was a Phase Ia open-label, non-randomized malaria vaccine trial. The clinical
trial protocol and supporting CONSORT checklist are available as Supporting
Information; see S1 Protocol, S1 Checklist and S1 File. Allocation to study groups
(Fig. 1) occurred at screening based on volunteers’ availability. Twelve volunteers
were vaccinated intramuscularly (IM) with 56109 vp ChAd63 CS (in 0.9% NaCl
and administered in 350 mL) (groups 1A & 1B). Eight of these volunteers were
subsequently vaccinated 56 days later with 26108 pfu MVA CS IM, undiluted and
administered in 340 mL (group 1B). Another twelve volunteers were vaccinated
IM with 561010 vp ChAd63 CS undiluted and administered in 350 mL(group 2A
& 2B) and eight of these were subsequently vaccinated 56 days with 26108 pfu
MVA CS undiluted and administered in 340 mL. All vaccines were administered in
the deltoid region, with volunteers in groups 1B & 2B receiving ChAd63 CS and
MVA CS in alternating arms.
Volunteers attended clinical follow-up at days 1, 14, 28, 56 and 90 following
ChAd63 CS immunization in groups 1A and 2A and at days 1, 14, 28, 56, 57, 63,
84 and 140 following ChAd63-CS immunization in groups 1B and 2B. Safety
assessments, including blood sampling for safety and immunology analysis at
these visits were conducted as previously described [29]. Participants were given a
diary in which to record adverse events (AEs). A time window ranging between 1
and 14 days was allowed for vaccination and follow-up visits.
Sample size
This was an observational and descriptive study to assess the safety and
immunogenicity of ChAd63 CS and MVA CS. The sample size (n524) was chosen
to allow determination of the magnitude of the primary outcome measures,
Safety and Immunogenicity of ChAd63 and MVA CS
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especially of serious and severe AEs, rather than assessment of statistically
significant differences between groups.
Ethical & Regulatory Approval
The trial VAC038 was registered on the European Medicines Agency database
(EudraCT 2011-001875-38). As the trial was initially planned to take place in sites
in the UK and Ireland, ethical and regulatory approval was sought from both UK
and Irish institutions. Regulatory approval for the study was granted by the UK
Medicine and Healthcare Regulatory Authority (MHRA) (ref. 21584/0285/001-
000) and by the Irish Medicines Board (CT number CT 900/516/2, Case number
2107330). Ethical approval was granted by the National Research Ethics
committee – South Central – Oxford A in the UK (ref. 11/SC/0289) and by the
Research Ethics committee of Beaumont Hospital in Ireland (ref. 11/58). Vaccine
use was authorized by the Environmental Protection Agency (EPA) of Ireland
(Reference number G0451-01) and by the Genetic Modification Committee of the
Oxford Radcliffe Hospitals trust (Ref. GM462.11.63). All participants gave written
informed consent prior to any study procedure being undertaken. The study was
conducted according to the principles of the Declaration of Helsinki (2008) and
the International Conference on Harmonization (ICH) Good Clinical Practice
(GCP) guidelines. The Local Safety Committee provided safety oversight and GCP
compliance was independently monitored by an external organization
(Appledown Clinical Research Ltd, Great Missenden, UK).
Safety
The first volunteer to receive each vaccine at each dose was vaccinated alone and
observed in clinic for 12 hours. They were then reviewed again in clinic 24 hours
post vaccination. Once 72 hours had elapsed and in the absence of safety
concerns, volunteers 2 and 3 were vaccinated with that vaccine and dose. Once
72 hours had elapsed, and in the absence of safety concerns, other volunteers were
administered the vaccine at the same dose. Apart from the first volunteer to
receive each vaccine at a particular dose, all volunteers were observed in clinic for
30 minutes after each immunization. Prior to dose escalation of the ChAd63 CS
vaccine from 56109 vp to 561010 vp, the independent data safety monitoring
board reviewed and approved a report of all safety data collected from volunteers
up to 14 days after receiving 56109 vp ChAd63 CS.
Volunteers were given a digital thermometer, injection site reaction measure-
ment tool and symptom diary card to record their daily temperature, injection site
reactions and solicited systemic AEs for 14 days following vaccination with
ChAd63 CS and 7 days following vaccination with MVA CS. Local and systemic
reactogenicity was evaluated at subsequent clinic visits and graded for severity,
outcome and association to vaccination as per the criteria outlined in S1, S2 and
S3 Tables. Blood was sampled at all visits post vaccination except days 1 and 57,
and the full blood count with differential, platelet count and serum biochemistry
Safety and Immunogenicity of ChAd63 and MVA CS
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(including electrolytes, urea, creatinine, bilirubin, alanine aminotransferase,
alkaline phosphatase and albumin) measured.
Peripheral Blood Mononuclear Cell (PBMC) and Serum
Preparation
Blood samples were collected into lithium heparin-treated Vacutainer blood
collection systems (Becton Dickinson, UK). PBMC were isolated and used within
6 hours in fresh assays as previously described [29]. Excess cells were frozen in
foetal calf serum (FCS) containing 10% dimethyl sulfoxide (DMSO) and stored in
liquid nitrogen. For serum preparation, untreated blood samples were stored at
4 C˚ and then the clotted blood was centrifuged for 5 min (1000 xg). Serum was
stored at 280 C˚.
Peptides for T cell Assays
Peptides (NEO Peptide, Cambridge, MA, USA), 15 amino acids (aa) in length and
overlapping by 10 aa spanning the entire CSP insert, were reconstituted in 100%
DMSO at 50–200 mg/mL and combined into various pools for ELISPOT and flow
cytometry assays. The composition of peptide pools containing 2 to 15 peptides
are listed in S5 Table CSP overlapping peptides.
Ex-vivo interferon-c (IFN-c) ELISPOT
The kinetics and magnitude of the T cell response to CSP were assessed over time
by ex-vivo IFN-c ELISPOT following an 18–20 hour re-stimulation of PBMC with
overlapping peptides spanning the entire CSP insert present in the viral vectored
vaccines (S5 Table peptides). Fresh PBMC were used in all ELISPOT assays using
a previously described protocol [29], except that CSP peptide pools (final
concentration each peptide 5 mg/mL) were added to test wells, culture medium
was added to negative un-stimulated wells, and Staphylococcal enterotoxin B
(SEB, Sigma) (final concentration 10 mg/mL) plus phytohemagglutinin (PHA,
Sigma) (final concentration 0.02 mg/mL), PPD (10 mg/mL) and FEC (pool of
peptides from influenza, Epstein Barr virus and cytomegalovirus, final
concentration 10 mg/mL, Neo peptide) was added to positive control wells [36].
Each well contained 200,000 PBMC. Spots were counted using an ELISPOT
counter (Autoimmun Diagnostika (AID), Germany). Results are expressed as
IFN-c spot-forming cells (SFC) per million PBMC. Background responses in un-
stimulated control wells were almost always less than 20 spots, and were
subtracted from those measured in peptide-stimulated wells. Responses are shown
as the summed response to all the CSP peptide pools (unless otherwise stated).
10% of all ELISPOT plates underwent a quality control (QC) procedure involving
review of time-lines of cell processing, visual inspection of plate, review of raw
data output and validation of positive and negative controls. Positive controls
were deemed valid if there were at least 200 spots in one of the positive control
wells (PHA, SEB or FEC). Two negative control wells containing only medium
Safety and Immunogenicity of ChAd63 and MVA CS
PLOS ONE | DOI:10.1371/journal.pone.0115161 December 18, 2014 7 / 26
and PBMC where required on each plate. In order to pass QC the mean count of
these two well had to be less than 20 spots per well.
Multiparameter Flow Cytometry
Responses were assessed by 7 colour flow cytometry, which was performed on
frozen PBMC, by stimulating aliquots of 16106 cells in 1 ml of medium
containing anti-CD28 and anti-CD49d at 1 mg/ml (Becton Dickinson) and 5 ml/
ml of CD107a-PeCy5 (eBioscience) with either no antigen, a pool of all 55
peptides spanning the T9/96 the CSP antigen (2 mg/ml) or a positive control,
Staphylococcal enterotoxin B (Sigma, 1 mg/ml), in 5 ml polystyrene FACS tubes
for 18 hours. Brefeldin A and Monensin, both at 1 mg/ml, were added for the last
16 hours. Cells were incubated with a dead cell discrimination dye (VIVID, 1/80,
Invitrogen), and then surface stained at 4 C˚ with CD4-APC (1/20, eBioscience) or
CD4-Qdot 625 (1/50, Invitrogen), CD14- and CD19-Pacific Blue (both 1/50,
Becton Dickinson). After permeabilisation, intracellular staining was performed at
room temperature with CD3-PeCy5 (part A, 1/20, eBioscience) or CD3-Alexa
Fluor 700 (part B, 1/100, eBioscience) plus CD8-APC-Alexa Fluor 780 (1/50) and
IFN-c-FITC (1/50), IL-2-PE (1/100) and TNFa-Pe-Cy7 (1/50, all eBioscience) and
fixed in 1% paraformaldehyde. Acquisition was performed on the day of staining
on a BD LSRII; at least 500,000 events were collected per sample. Data was
prepared and analysis performed using FlowJo v8.8.6 (Treestar Inc,), Pestle v1.6
and Spice v5.05 (Mario Roederer, Vaccine Research Centre, NIAID, NIH). Dead
cells (Vivid+), monocytes (CD14+), and B cells (CD19+) were excluded from the
analysis. A time gate was first evaluated, and then cells were gated on lymphocytes,
singlets, live CD3+, CD8+ or CD4+ (excluding double-positives), and then IFNc
and combinations of markers. A sample gating strategy is provided in S1 Figure.
Responses were determined after subtraction of the response in the unstimulated
control for each sample. Pie charts were created using absolute measures with a
threshold of 0.001%. MFI (Mean Fluorescence Integrity) was calculated using the
geometric mean of the cytokine-positive population and iMFI (integrated MFI)
represents the integration of the frequency with the geometric mean of the
cytokine-secreting population, giving a measure of total amount of cytokine
production.
Total IgG ELISA and Human IFA
Anti-CSP antibodies were measured at Walter Reed Army Institute of Research,
by enzyme-linked immunosorbent assay (ELISA) against the CSP repeat region
using a hexameric synthetic peptide (NANP)6 (CSPrp ((NANP)6 Peptide [100 mg/
mL] Eurogentec Cat: EP070034 Lot: 14) and immunofluorescent antibody assay
(IFA) using air-dried sporozoites. (S2 File for details of assay).
Safety and Immunogenicity of ChAd63 and MVA CS
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Statistical Analysis
Data were analyzed using GraphPad Prism version 5.04 for Windows (GraphPad
Software Inc., California, USA). Geometric mean or median responses for each
group are described. Kruskall-Wallis test was used for one-way analysis of variance
by ranks. Significance testing of differences between two groups used the two-
tailed Mann-Whitney U test or Wilcoxon signed rank test as appropriate. No
corrections for multiple hypothesis testing were used.
Results
Study Recruitment
Recruitment took place between December 2011 and July 2012. Twenty-four
healthy malaria-nai¨ve adult volunteers (12 female and 12 male) were enrolled,
immunized and followed up (Fig. 1). The mean age of volunteers was 30 years
(range 21–46). Full demographic information on volunteers is available in S6
Table. Vaccinations began in January 2012 and all follow-up visits were completed
by November 2012. All volunteers attended all visits as scheduled and completed
the study.
Safety and Reactogenicity
No unexpected or serious AEs occurred and no volunteers were withdrawn due to
AEs.
Table 1 provides details of AEs deemed possibly, probably or definitely related
to vaccination. ChAd63 CS demonstrated a good safety profile with the majority
of AEs being mild in severity (91%) and 80% of all AEs resolved within 48 hours
(Figs. 2 & 3). Overall, 14 out of 24 volunteers (58%) experienced one or more
local AEs related to ChAd63 CS; all of which were mild. 20 out of 24 volunteers
(83%) experienced one or more systemic AE related to ChAd63 CS and a dose
response was seen for systemic reactogenicity, with a greater proportion of
volunteers receiving 561010 vp experiencing a systemic AE than volunteers
receiving 56109 vp. The majority of these AEs were mild in severity. MVA CS
administered 8 weeks after the ChAd63 CS was more reactogenic, with 14 out of
16 volunteers (87%) experiencing at least one local AEs, mainly pain, erythema
and warmth. 15 volunteers (93%) experienced at least one systemic AEs, including
feverishness, myalgia, fatigue, malaise and headache in the 24 hours following
vaccination, though the majority of these were mild in severity. This AE profile is
similar to the flu-like symptoms that have been reported in the past with similar
doses of MVA vectored vaccines expressing other antigens [20, 22, 29–32, 37–40].
The neutrophil count of one volunteer dropped from 1.566109/L at screening to
1.096109/L 28 days post vaccination with ChAd63 CS at a dose of 56109 vp and
remained less than 1.566109/L throughout follow up.
Safety and Immunogenicity of ChAd63 and MVA CS
PLOS ONE | DOI:10.1371/journal.pone.0115161 December 18, 2014 9 / 26
ChAd63-MVA CS T cell immunogenicity assessed by ex-vivo IFN-c
ELISPOT
Antigen-specific T cell responses in all volunteers as measured by ex-vivo IFN-c
ELISPOT are shown in Fig. 4. When comparing the responses to two different
doses of ChAd63 CS, no significant difference was seen between group 1 (ChAd63
56109 vp) and group 2 (ChAd63 CS 561010 vp) at the peak of the response on
day 14 (median 423 [range 12.5–1590] vs 178 [range 52.5–1795] SFC/million
PBMCs, p50.54 Mann-Whitney test). Thereafter T cell responses gradually
contracted to day 56 (Fig. 4). Administration of MVA CS at day 56 significantly
boosted responses in all volunteers as measured 7 days later on day 63 (Fig. 4). No
Table 1. Local, systemic and laboratory adverse events post immunization.
Sign or
Symptom ChAd63 CS 56109 ChAd63 CS 561010 MVA CS
N512 N512 N516
(% of volunteers) (% of volunteers) (% of volunteers)
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
LOCAL
Pain 2(17%) 0 0 7(58%) 0 0 9(56%) 5(31%) 1(6%)
Erythema 4(33%) 0 0 3(25%) 0 0 5(31%) 1(6%) 0
Warmth 0 0 0 4(33%) 0 0 6(37%) 0 0
Swelling 2(17%) 0 0 1(8%) 0 0 2(12%) 0 0
Scaling 1(8%) 0 0 1(8%) 0 0 1(6%) 0 0
Pruritis 0 0 0 1(8%) 0 0 0 0 0
Other 2(17%) 0 0 1(8%) 0 0 0 0 0
Total local AEs 11 0 0 18 0 0 23 6 1
SYSTEMIC
Fever 0 0 0 3(25%) 0 0 2(12%) 0 0
Feverish 1(8%) 0 0 2(17%) 0 0 5(31%) 0 1(6%)**
Arthralgia 0 0 0 5(42%) 0 0 4(25%) 0 0
Myalgia 2(17%) 0 0 6(50%) 0 0 7(44%) 0 1(6%)**
Malaise 0 0 0 1(8%) 0 0 5(31%) 0 0
Fatigue 3(25%) 0 0 5(42%) 1(8%) 1(8%) 10(62%) 0 0
Headache 2(17%) 0 0 6(50%) 0 0 8(50%) 0 1(6%)**
Nausea 0 0 0 2(17%) 0 0 3(19%) 0 0
Vomiting 0 0 0 0 0 0 0 0 0
Other systemic 1(8%) 0 0 2(17%) 0 0 4(25%) 0 0
Laboratory 1(8%)* 0 0 0 0 0 1(6%)* 0 0
Total systemic
AEs
10 0 0 32 1 1 49 0 3
Adverse events deemed possibly, probably or definitely related to vaccination are shown. ‘Other systemic’ following MVA CS included nasal congestion,
laryngitis and pharyngitis. The highest intensity adverse event per subject is listed. Other local AEs included paraesthesia. All ‘other’ AEs were considered
possibly related to vaccination due to a temporal association.
*The two laboratory AEs related to the same volunteer, who experienced neutropenia following both vaccination.
**Three severe systemic AEs followed MVA CS, all experienced by one volunteer simultaneously and resolved within 48 hours of vaccination.
doi:10.1371/journal.pone.0115161.t001
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significant difference was seen when comparing day 63 ELIspot responses between
groups 1B & 2B (median 1523, [range 380–4125] vs 1048 [range 320–5450] SFC/
million PBMCs in groups 1B and 2B respectively, n58 v 8, p50.5 Mann-Whitney
test). ELIspot responses subsequently contracted but remained above baseline
Fig. 2. Local and systemic adverse events (AEs) possibly, probably or definitely related to vaccination shown as percentage of volunteers
affected. (a) Post ChAd63 CS 56109 vp; (b) Post ChAd63 CS 561010 vp; (c) Post MVA CS 26108 pfu.
doi:10.1371/journal.pone.0115161.g002
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Fig. 3. The mean duration and range of duration of local and systemic AEs possibly, probably or definitely related to vaccination. (A) post ChAd63
CS 56109 vp; (B) post ChAd63CS 561010 vp; (C) post MVA CS.
doi:10.1371/journal.pone.0115161.g003
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when measured at the last time-point, day 140, (median 1B 346.25 [range 17.5–
1607], median 2B 176 [range 102–707] SFC/million PBMCs), Fig. 4. There was no
significant difference between the groups at this time-point (p50.16 Mann-
Whitney test). Median ELISPOT response in groups 1B and 2B were significantly
different when all time-points were analysed (p,0.0001 for both groups,
Kruskall-Wallis). The changes were significant over time; group 1B, day 0 to 14
p50.0063; day 14 to 63 p50.0148; day 0 to 63 p50.0002, Mann-Whitney test;
group 2B, day 0 to 14 p50.01; day 14 to 63 p50.0074; day 0 to 63 p50.0002,
Mann-Whitney test. This was not seen with groups 1A and 2A, p50.66 and
p50.014 respectively, Kruskall-Wallis.
Breadth of the CSP T cell response
T cell responses in all volunteers were detected in multiple peptide pools spanning
the entire CSP vaccine insert in the ex-vivo IFN-c ELISPOT assay, (Fig. 5).
Following priming immunization with ChAd63 CS individual responses were
seen across all pools with no apparent immune-dominant region in CS detected.
One week post boost with MVA CS, responses were again observed across all
pools. Pools 1, 2, 5, 6 showed a significant increase in ELISPOT response when
comparing pre and post boost results, with p values of 0.0229, 0.0021, 0.0227,
0.0026 respectively (Wilcoxon matched pairs signed rank test).
The 6 highest responders at day 63 were assessed by ex-vivo IFN-c ELISPOT for
responses to single peptides in an attempt to map the most immunogenic epitopes
of the CS insert. Median responses to peptides 1 to 43 (15 mer peptides
overlapping by 10aa) are shown in Fig. 6. Peptides 1, 3, 5, 8, 42 and 43 were
identified as containing dominant epitopes, although it is likely that there is a
single epitope spanning peptides 42 and 43.
CSP T cell multi-functionality
Antigen-specific CD3+ T cell functionality was also assayed by ICS at the days 14,
63 and 84/90 time-points. Following peptide re-stimulation, detectable CSP-
specific CD3+ T cells consisted of a mixed CD4+ and CD8+ phenotype, Fig. 7. It
should be noted that the ELISpot and intracellular cytokine staining (ICS) assays
vary in methodology (including the use of multiple versus a single peptide pool
respectively, differences in peptide concentration, use of co-stimulatory antibodies
and the use of fresh versus frozen PBMC). As no difference in ELIspot response
was seen between volunteers receiving different doses of ChAd63 CS, data for ICS
was combined across groups 1B & 2B and assays were performed where cell
Fig. 4. Summary of PBMC IFN-y ELIspot responses of volunteers in each group. Summed SFC/million PBMCs. (A) and (B) individual responses for
groups 1A and 1B respectively over time. (C) and (D) show individual responses for groups 2A and 2B respectively over time. (E) median ELIspot response
by group by time-point, changes were significant over time; for group 1B, day 0 to 14 p50.0063; day 14 to 63 p50.0148; day 0 to 63 p50.0002, Mann-
Whitney test; and group 2B, day 0 to 14 p50.01; day 14 to 63 p50.0074; day 0 to 63 p50.0002, Mann-Whitney test. (F), (G) & (H) show individual
responses by group at days 14, 63 and 84 or 90 respectively.
doi:10.1371/journal.pone.0115161.g004
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Fig. 5. Individual ELISpot responses in SFC/106 PBMC at day 63 by peptide pool. Bar represents mean, whiskers; standard error of the mean.
doi:10.1371/journal.pone.0115161.g005
Fig. 6. Median & Interquartile range ELISpot responses in SFC/106 PBMC at day 63 by peptide. Box plots of the medians and 25% and 75% percentiles
of response to each peptide. The first and third quartiles are the top and base of each box, the upper and lower bars represent the maximum and minimum
values respectively.
doi:10.1371/journal.pone.0115161.g006
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numbers allowed. Fig. 8 presents the relative proportion of multifunctional cells
at the peak observed at day 63, it does not provide detail on which cytokine is
being produced.
Across all three time-points analysed CD107a (marker of degranulation)
expression was up-regulated by both CD4+ and CD8+ T cells. Fig. 9. CD4+ cells
produced higher levels of TNFa than CD8+ cells at all time-points, but this was
not statistically significant (p50.58, p50.31 and p50.48 for days 14, 63 and 84
respectively, Mann-Whitney test). CD4+ cells also produced greater levels of IL-2
compared to CD8+ cells at all time-points, however this did not reach significance
(p50.77, P50.59 and p50.32 for days 14, 63 and 84 respectively, Mann-Whitney
test). Negligible levels of IFN-c were produced by either CD4+ or CD8+ cells at
days 14 and 63. Levels comparable to IL-2 and TNFa were observed at day 84.
Distinct populations of CD4+ and CD8+ T cells expressing 1+, 2+, 3+ or 4+
functional markers/cytokines were evident following a Boolean gate analysis
(Fig. 7 and S7 Table).
Fig. 7. T cell multi-functionality following ChAd63-MVA CS immunization. The multi-functionality of the CD4+ and CD8+ Tcell responses was assessed
by polychromatic flow cytometry and ICS. Frozen PBMCs from day 63 were re-stimulated with a pool of CSP peptides and cells stained as described in
methods above. Gating strategy and representative plots are shown in S1 Figure. Responses are grouped and colour-coded according to the CD4+ and
CD8+ subsets, and the number of functions detected for each T cell population. Individual data points showing the percentage of the parent CD4+ or CD8+
response are shown for each of the functional populations indicated on the X-axis. The pie charts summarize the fractions of CSP specific CD4+ or CD8+ T
cells that are positive for a given number of functions (CD107a, IFNc, IL-2 and TNFa). The row at the base of the figure labelled ‘pie chart’ provides a key to
the colours of pie segments, the darkest colours representing cells that produced 4 cytokines and the lightest colour producing one.
doi:10.1371/journal.pone.0115161.g007
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ChAd63-MVA CS antibody immunogenicity assessed by ELISA
and Immuno-fluorescence assay (IFA)
The kinetics and magnitude of the serum IgG antibody response against CS were
assessed over time by ELISA (Fig. 10). All volunteers had IgG titres below the limit
of detection at day zero. CS-specific IgG was induced in all volunteers. Mean
responses peaked at day 14 with CS antibody titre of 631 and 713 for groups
1(A&B) and 2(A&B) respectively. Boosting with MVA CS resulted in a significant
increase in antibody concentration in group 1B, compared to the un-boosted
group 1A, as measured at day 84/90 (p50.037; Mann-Whitney test). However this
was not seen when comparing groups 2A and 2B at the same time-points (p50.49
Mann-Whitney test). Mean antibody response was higher in group 2B compared
to group 1B at day 140, but this difference was not statistically significant (p50.87
Mann-Whitney test). Samples from any volunteer with ELISA titres above the
Lower limit of detection (LLD) at both day 28 and 84/90 post ChAd63 CS, were
also assessed by IFA. No significant boosting effect was observed in either group
1B and 2B when analysing by IFA, p50.08 (Mann-Whitney test).
Fig. 8. Multifunctional antigen specific cells. Percent of CD4+ and CD8+ PBMCs at day 63 producing 1–4 cytokines following stimulation with CS peptide
pools.
doi:10.1371/journal.pone.0115161.g008
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HLA typing and immune response
Previous studies have identified class I and II CSP epitopes and their HLA
restriction, [41–43] so all volunteers were typed for major HLA types; A, B and
DR (S4 Table). The apparent immune-dominance of peptide pools 1 and 6 may
be explained by the fact that HLA super types A1 and A2, predominate in our
volunteers and that it has previously been shown that epitopes contained within
these pools are restricted to these HLA super types.
Fig. 9. Cytokine production by cell type and time-point assessed by 7 colour flow cytometry. Mean percent and standard error of the mean (SEM) of
CD4+ and CD8+ PBMCs producing antigen-specific cytokines at given time-point post vaccination are shown for each cytokine. (A) percent CD4+ and (B)
percent CD8+ PBMCs producing CD107a, IFNg, IL2 and TNFa at day 63. (C) percent CD4+ and (D) percent CD8+ PBMCs producing CD107a, IFNg, IL2
and TNFa at day 63. (E) percent CD4+ and (F) percent CD8+ PBMCs producing CD107a, IFNg, IL2 and TNFa at day 84.
doi:10.1371/journal.pone.0115161.g009
Fig. 10. Summary IgG antibody titre against CS. (A) Mean serum IgG ELISA antibody response against CS
over time in days post vaccination are shown. (B) individual and geomean antibody responses by group and
time point. ** p,0.05 by Mann-Whitney test.
doi:10.1371/journal.pone.0115161.g010
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Discussion
Here we have shown in a first in human phase Ia study, that ChAd63-CS and
MVA–CS have acceptable safety profiles, and are potently immunogenic, inducing
high levels of antigen-specific multifunctional CD4+ and CD8+ T lymphocytes,
and significant levels of antibody.
Safety
No serious adverse events occurred during the course of the trial. The majority of
AEs observed were mild in intensity and resolved rapidly. Over 300 healthy
volunteers have now received ChAd63 encoding the malaria antigens ME-TRAP,
MSP1 and AMA1 [18, 20–22, 31, 44]. The safety profile seen with ChAd63 CS was
very similar to that of other ChAd63 vectored vaccines. [20–22, 29] MVA CS at a
dose of 26108 was considerably less reactogenic than was observed at higher or
same dose of MVA expressing different antigens [20] [22, 29]. 1226108 pfu has
consistently been shown to be the optimal dose of MVA [20, 22, 24, 28, 30, 32, 38–
40, 44]. The majority of volunteers who received MVA CS experienced a range of
symptoms comprising of feverishness, fatigue, headache and myalgia. These were
mild in severity in the majority of cases and all resolved within 48 hours.
Comparing ChAd63 CS to NMRC-M3V-Ad-PfC, the other viral vectored CS
vaccine which has been studied in humans, both result in mainly mild local and
systemic AEs. ChAd63 CS at both doses resulted in less local pain than NMRC-
M3V-Ad-PfC; with 17%, 58%, 67% and 86% of volunteers experiencing injection
site pain following ChAd CS(56109 vp), ChAd CS(561010vp) and NMRC-M3V-
AdPfC, first immunization and second immunization, respectively [41]. ChAd63
CS, at either dose, resulted in local erythema in a higher percentage of volunteers,
33%(56109vp) and 25%(561010vp) than NMRC-M3V-Ad-PfC, 0% [41].
ChAd63 CS at the higher dose (561010vp) was also more reactogenic in terms of
the systemic AEs of myalgia, headache and fatigue, than NMRC-M3V-Ad-PfC,
but the majority were of mild severity and resolved within 48 hours [41]. The
safety data collected in this study adds to the already significant body of data
supporting the excellent safety profile of this vaccine delivery platform.
Immunogenicity
MVA expressing CS has been studied in humans in the past and IFN c ELIspot
results have varied from a mean of 79 SFC/106 PBMC when combined with DNA
prime [18], to 250 SFC/106 PBMC, when primed with RTS,S, to 1000 SFC/106
PBMC when primed by attenuated fowl-pox virus (FP9) [45]. ChAd63–MVA
vectored vaccines have consistently yielded high levels of T-cells
[20–22, 24, 28, 29, 44]. Despite the fact that CS was one of the earliest recognised
target antigens in the development of a malaria vaccine, it remains a leading
antigen for vaccine development. Others have also recently published data on a
human adenovirus vectored vaccine expressing CS (NMRC-M3V-Ad-PfCA),
which yielded a peak mean IFN c ELISpot CS of 422 SFC/million [41, 42].
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ChAd63 –MVA CS yielded a peak mean three fold greater at 1523 SFC/million.
Protection assessed by controlled human malaria infection was disappointing in
the case of NMRC-M3V-Ad-PfCA, with 2/11 volunteers showing delayed onset of
parasitaemia with no volunteer protected [41]. Peak antibody responses to CS for
both vaccines measured by ELISA were modest, with NMRC-M3V-Ad-PfCA
yielding median ELISA titres of 300 [41], 692 [42] and Ch63-MVA CS yielding a
median titre of 631. RTS,S is the malaria vaccine most advanced in clinical
development and is currently undergoing phase 3 trials [46]. It is formed from the
fusion of CS to the surface antigen of hepatitis B virus to form virus-like particles.
Analysis of the immunological correlates of immunity induced by the RTS,S/AS01
vaccine and adjuvant suggest that very high levels of antibodies to CS correlate
with protection in humans [47, 48]. However, this correlation is relatively weak
and there might be a component of T cell mediated protection induced by the
vaccine, even though the magnitude of the T cell response measured after
vaccination is modest (mean of approximately 150 SFU/million PMBCs on
ELIspot) [49, 50]. The prime-boost strategy of the viral vectored vaccines, ChAd63
and MVA both expressing CS presented here, has produced T cells responses
much greater (mean 1,947 SFC/million PMBCs on ELIspot) than RTS,S. The
production of CD8+ monofunctional cytokine producing cells which has been
shown here (Fig. 8), has been correlated with protection to controlled human
malaria challenge in the past [28]. The breadth of the ELISPOT response observed
may also be relevant to efficacy. The greater magnitude of T-cell immunogenicity
induced by ChAd-MVA heterologous prime-boost immunization correlates with
an increase in the number of detectable epitopes recognized [21, 49, 51] so it is
likely that increased breadth also correlates with efficacy.
CSP specific antibody responses seen with ChAd63 CS followed by MVA CS
were modest (mean of 1.9 mg/mL for groups 1B and 2B 7 days post MVA CS). In
contrast RTS,S has yielded mean antibody responses of 78 mg/mL in non-immune
adult vaccinees [51]. The significant levels of T cells yielded by vaccination with
ChAd63 MVA CS and the high antibody levels produced by RTS,S, raises the
possibility that combining the platforms to provide potentially complementary
immune responses might provide better protection. There may also be benefit in
combining ChAd63 MVA CS with other antigens, also delivered by the same viral
vectors which shown to have protective efficacy [28].
Limitations of the study include the small numbers and fact that volunteers
were malaria nai¨ve. However both of these were requirements given that it was the
first time that these products were administered to humans. There was no placebo
group, however, these vectors, expressing a range of antigens, have been
administered to over 460 individuals and have shown a consistent reactogenicity
profile. The next stage in development is controlled human malaria challenge,
where an unvaccinated control group is used.
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Conclusions
Given the excellent safety profile show here ChAd63 MVA CS should progress to
Phase IIa efficacy study in adults with controlled human malaria infection. These
vaccines could have a role in protection against malaria when used together, or
combined with other vaccines.
Supporting Information
S1 Figure. Gating strategy for analysis of CSP-specific T cell responses.
Representative flow cytometry plots are shown for the analysis of CSP-specific T
cell responses from volunteers immunized with ChAd63-MVA CSP. (A) Initial
gating used (from top left to bottom right) forward scatter area (FSC-A) versus
forward scatter height (FSC-H) to remove doublet events and select singlet cells;
then following this small lymphocytes were gated using FSC-A versus side scatter
area (SSC-A); then live CD142 CD202 CD3+ cells were selected; then CD4 versus
CD8 was used to select the total CD4+ CD82 cell population and vice versa for the
CD8+ CD42 population. Cytokine (IFN-c, IL-2 and TNFa) and CD107a gating
using bivariate plots is shown for (B) CD4+ cells and (C) CD8+ cells. (B)
Representative plots for un-stimulated (UNS), CS peptide stimulated (CS), SEB
stimulated samples are shown. IFN-c (top row), IL-2 (second row), TNFa (third
row) and CD107a (bottom row) for the CD82 CD4+ T cell population were
analyzed using bivariate plots. Percentages refer to the % of CD82 CD4+ cells that
express the specific cytokine or marker. Background responses in UNS control
cells were subtracted from the CS response respectively during the analysis. (C)
Same analysis as in (B), except for the CD42 CD8+ T cell population.
doi:10.1371/journal.pone.0115161.s001 (TIF)
S1 Table. Assessment of severity of AEs.
doi:10.1371/journal.pone.0115161.s002 (TIF)
S2 Table. Assessment of severity of local AEs.
doi:10.1371/journal.pone.0115161.s003 (TIF)
S3 Table. Assessment of relationship of AE to vaccination.
doi:10.1371/journal.pone.0115161.s004 (TIF)
S4 Table. HLA typing of all volunteers enrolled in study.
doi:10.1371/journal.pone.0115161.s005 (TIF)
S5 Table. CSP overlapping peptides. Peptides (NEO Peptide, Cambridge, MA,
USA), 15 amino acids (aa) in length and overlapping by 10 aa spanning the entire
CSP insert, were reconstituted in 100% DMSO at 50–200 mg/mL and combined
into various pools for ELISPOT and flow cytometry assays. The composition of
peptide pools containing to 2 to 15 peptides is shown here.
doi:10.1371/journal.pone.0115161.s006 (TIF)
S6 Table. Demographic of study volunteers.
doi:10.1371/journal.pone.0115161.s007 (TIF)
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S7 Table. Day 63 Multi-functional cells. Percent of parent population (CD4+ or
CD8+) producing 1 or more cytokine by group.
doi:10.1371/journal.pone.0115161.s008 (TIF)
S1 Checklist. CONSORT Checklist.
doi:10.1371/journal.pone.0115161.s009 (DOC)
S1 File. Inclusion and exclusion criteria for volunteers in study.
doi:10.1371/journal.pone.0115161.s010 (PDF)
S2 File. Total IgG ELISA and IFA assays used.
doi:10.1371/journal.pone.0115161.s011 (PDF)
S1 Protocol. Clinical trial protocol.
doi:10.1371/journal.pone.0115161.s012 (PDF)
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